Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60


FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.

Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, Taylor KN, Barrie AM, Jiang S, Bean LM, Sulzmaier FJ, Jean C, Tancioni I, Anderson K, Uryu S, Cordasco EA, Li J, Chen XL, Fu G, Ojalill M, Rappu P, Heino J, Mark AM, Xu G, Fisch KM, Kolev VN, Weaver DT, Pachter JA, Győrffy B, McHale MT, Connolly DC, Molinolo A, Stupack DG, Schlaepfer DD.

Elife. 2019 Sep 3;8. pii: e47327. doi: 10.7554/eLife.47327.


Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.

Jiang H, Liu X, Knolhoff BL, Hegde S, Lee KB, Jiang H, Fields RC, Pachter JA, Lim KH, DeNardo DG.

Gut. 2020 Jan;69(1):122-132. doi: 10.1136/gutjnl-2018-317424. Epub 2019 May 10.


Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedrés S, Nolan L, Kindler H, Aerts JGJV.

J Clin Oncol. 2019 Apr 1;37(10):790-798. doi: 10.1200/JCO.2018.79.0543. Epub 2019 Feb 20.


A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.

Feng X, Arang N, Rigiracciolo DC, Lee JS, Yeerna H, Wang Z, Lubrano S, Kishore A, Pachter JA, König GM, Maggiolini M, Kostenis E, Schlaepfer DD, Tamayo P, Chen Q, Ruppin E, Gutkind JS.

Cancer Cell. 2019 Mar 18;35(3):457-472.e5. doi: 10.1016/j.ccell.2019.01.009. Epub 2019 Feb 14.


PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.

Muz B, Buggio M, Azab F, de la Puente P, Fiala M, Padval MV, Weaver DT, Pachter JA, Vij R, Azab AK.

Haematologica. 2019 Jul;104(7):e310-e313. doi: 10.3324/haematol.2018.194688. Epub 2019 Jan 17. No abstract available.


Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.

Mukhopadhyay A, Drew Y, Matheson E, Salehan M, Gentles L, Pachter JA, Curtin NJ.

Biochem Pharmacol. 2019 Sep;167:125-132. doi: 10.1016/j.bcp.2018.10.011. Epub 2018 Oct 17.


The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.

Murakami Y, Sonoda K, Abe H, Watari K, Kusakabe D, Azuma K, Kawahara A, Akiba J, Oneyama C, Pachter JA, Sakai K, Nishio K, Kuwano M, Ono M.

Oncotarget. 2017 Aug 7;8(41):70736-70751. doi: 10.18632/oncotarget.19982. eCollection 2017 Sep 19.


Inhibition of FAK kinase activity preferentially targets cancer stem cells.

Kolev VN, Tam WF, Wright QG, McDermott SP, Vidal CM, Shapiro IM, Xu Q, Wicha MS, Pachter JA, Weaver DT.

Oncotarget. 2017 Jun 16;8(31):51733-51747. doi: 10.18632/oncotarget.18517. eCollection 2017 Aug 1.


The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.

Begum A, Ewachiw T, Jung C, Huang A, Norberg KJ, Marchionni L, McMillan R, Penchev V, Rajeshkumar NV, Maitra A, Wood L, Wang C, Wolfgang C, DeJesus-Acosta A, Laheru D, Shapiro IM, Padval M, Pachter JA, Weaver DT, Rasheed ZA, Matsui W.

PLoS One. 2017 Jul 10;12(7):e0180181. doi: 10.1371/journal.pone.0180181. eCollection 2017.


Focal Adhesion Kinase as a Potential Target in AML and MDS.

Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M.

Mol Cancer Ther. 2017 Jun;16(6):1133-1144. doi: 10.1158/1535-7163.MCT-16-0719. Epub 2017 Mar 7.


Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo DG.

Nat Med. 2016 Aug;22(8):851-60. doi: 10.1038/nm.4123. Epub 2016 Jul 4.


Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL.

Churchman ML, Evans K, Richmond J, Robbins A, Jones L, Shapiro IM, Pachter JA, Weaver DT, Houghton PJ, Smith MA, Lock RB, Mullighan CG.

JCI Insight. 2016;1(4). pii: 86082. doi: 10.1172/jci.insight.86082. Epub 2016 Apr 7.


Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.

Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, Gómez-Cuadrado L, Canel M, Muir M, Ring JE, Maniati E, Sims AH, Pachter JA, Brunton VG, Gilbert N, Anderton SM, Nibbs RJ, Frame MC.

Cell. 2015 Sep 24;163(1):160-73. doi: 10.1016/j.cell.2015.09.001.


Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.

Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Nguyen T, Ring JE, Matsui W, MacLeod AR, Pachter JA, Hazlehurst LA, Koomen JM, Shain KH.

Oncogene. 2016 May;35(21):2723-34. doi: 10.1038/onc.2015.334. Epub 2015 Sep 21.


PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.

Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, Ricono J, Weaver DT, Padval MV, Pachter JA, Xu Q.

Cancer Res. 2015 Jan 15;75(2):446-55. doi: 10.1158/0008-5472.CAN-14-1223. Epub 2014 Nov 28.


Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics.

Jin M, Petronella BA, Cooke A, Kadalbajoo M, Siu KW, Kleinberg A, May EW, Gokhale PC, Schulz R, Kahler J, Bittner MA, Foreman K, Pachter JA, Wild R, Epstein D, Mulvihill MJ.

ACS Med Chem Lett. 2013 May 23;4(7):627-31. doi: 10.1021/ml400160a. eCollection 2013 Jul 11.


Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, Weaver DT, Menges C, Padval M, McClatchey AI, Xu Q, Testa JR, Pachter JA.

Sci Transl Med. 2014 May 21;6(237):237ra68. doi: 10.1126/scitranslmed.3008639.


Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.

Menges CW, Kadariya Y, Altomare D, Talarchek J, Neumann-Domer E, Wu Y, Xiao GH, Shapiro IM, Kolev VN, Pachter JA, Klein-Szanto AJ, Testa JR.

Cancer Res. 2014 Feb 15;74(4):1261-1271. doi: 10.1158/0008-5472.CAN-13-2062. Epub 2013 Dec 26.


Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.

Jin M, Wang J, Kleinberg A, Kadalbajoo M, Siu KW, Cooke A, Bittner MA, Yao Y, Thelemann A, Ji Q, Bhagwat S, Mulvihill KM, Rechka JA, Pachter JA, Crew AP, Epstein D, Mulvihill MJ.

Bioorg Med Chem Lett. 2013 Feb 15;23(4):979-84. doi: 10.1016/j.bmcl.2012.12.042. Epub 2012 Dec 21.


ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion.

Vigil D, Kim TY, Plachco A, Garton AJ, Castaldo L, Pachter JA, Dong H, Chen X, Tokar B, Campbell SL, Der CJ.

Cancer Res. 2012 Oct 15;72(20):5338-47. doi: 10.1158/0008-5472.CAN-11-2373. Epub 2012 Aug 31.


Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.

Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA.

Mol Cancer Ther. 2011 Aug;10(8):1394-406. doi: 10.1158/1535-7163.MCT-10-1099. Epub 2011 Jun 14.


Inducible expression of TGFβ, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model.

Argast GM, Krueger JS, Thomson S, Sujka-Kwok I, Carey K, Silva S, O'Connor M, Mercado P, Mulford IJ, Young GD, Sennello R, Wild R, Pachter JA, Kan JL, Haley J, Rosenfeld-Franklin M, Epstein DM.

Clin Exp Metastasis. 2011 Oct;28(7):593-614. doi: 10.1007/s10585-011-9394-8. Epub 2011 Jun 4.


Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.

Crew AP, Bhagwat SV, Dong H, Bittner MA, Chan A, Chen X, Coate H, Cooke A, Gokhale PC, Honda A, Jin M, Kahler J, Mantis C, Mulvihill MJ, Tavares-Greco PA, Volk B, Wang J, Werner DS, Arnold LD, Pachter JA, Wild R, Gibson NW.

Bioorg Med Chem Lett. 2011 Apr 1;21(7):2092-7. doi: 10.1016/j.bmcl.2011.01.139. Epub 2011 Feb 3.


Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.

Jin M, Kleinberg A, Cooke A, Gokhale PC, Foreman K, Dong H, Siu KW, Bittner MA, Mulvihill KM, Yao Y, Landfair D, O'Connor M, Mak G, Pachter JA, Wild R, Rosenfeld-Franklin M, Ji Q, Mulvihill MJ.

Bioorg Med Chem Lett. 2011 Feb 15;21(4):1176-80. doi: 10.1016/j.bmcl.2010.12.094. Epub 2010 Dec 23.


Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR.

Jin M, Gokhale PC, Cooke A, Foreman K, Buck E, May EW, Feng L, Bittner MA, Kadalbajoo M, Landfair D, Siu KW, Stolz KM, Werner DS, Laufer RS, Li AH, Dong H, Steinig AG, Kleinberg A, Yao Y, Pachter JA, Wild R, Mulvihill MJ.

ACS Med Chem Lett. 2010 Aug 30;1(9):510-5. doi: 10.1021/ml100178g. eCollection 2010 Dec 9.


Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-β enhances epithelial to mesenchymal transition in lung and pancreatic tumor models.

Argast GM, Mercado P, Mulford IJ, O'Connor M, Keane DM, Shaaban S, Epstein DM, Pachter JA, Kan JL.

Cells Tissues Organs. 2011;193(1-2):114-32. doi: 10.1159/000320179. Epub 2010 Nov 2.


Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.

Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, Epstein D, Pachter JA, Miglarese MR.

Mol Cancer Ther. 2010 Oct;9(10):2652-64. doi: 10.1158/1535-7163.MCT-10-0318. Epub 2010 Oct 5.


A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts.

Wang Y, Lipari P, Wang X, Hailey J, Liang L, Ramos R, Liu M, Pachter JA, Bishop WR, Wang Y.

Mol Cancer Ther. 2010 Feb;9(2):410-8. doi: 10.1158/1535-7163.MCT-09-0555. Epub 2010 Feb 2.


High-throughput screening for mTORC1/mTORC2 kinase inhibitors using a chemiluminescence-based ELISA assay.

Bhagwat SV, Kahler J, Yao Y, Maresca P, Brooks M, Crew A, Boisclair M, Pachter JA.

Assay Drug Dev Technol. 2009 Oct;7(5):471-8. doi: 10.1089/adt.2008.0183.


Quantitative high-throughput cell-based assays for inhibitors of ROCK kinases.

Garton AJ, Castaldo L, Pachter JA.

Methods Enzymol. 2008;439:491-500. doi: 10.1016/S0076-6879(07)00433-8.


A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.

Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O'Connor M, Yao Y, Pirritt C, Buck E, Eyzaguirre A, Arnold LD, Gibson NW, Pachter JA.

Mol Cancer Ther. 2007 Aug;6(8):2158-67. Epub 2007 Aug 1.


Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches.

Wang Y, Ji QS, Mulvihill M, Pachter JA.

Recent Results Cancer Res. 2007;172:59-76. Review. No abstract available.


RNA interference targeting of A1 receptor-overexpressing breast carcinoma cells leads to diminished rates of cell proliferation and induction of apoptosis.

Mirza A, Basso A, Black S, Malkowski M, Kwee L, Pachter JA, Lachowicz JE, Wang Y, Liu S.

Cancer Biol Ther. 2005 Dec;4(12):1355-60. Epub 2005 Dec 21.


Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody.

Wang Y, Hailey J, Williams D, Wang Y, Lipari P, Malkowski M, Wang X, Xie L, Li G, Saha D, Ling WL, Cannon-Carlson S, Greenberg R, Ramos RA, Shields R, Presta L, Brams P, Bishop WR, Pachter JA.

Mol Cancer Ther. 2005 Aug;4(8):1214-21.


Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells.

Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter JA, Wang Y.

Mol Cancer Ther. 2002 Dec;1(14):1349-53.


Compounds capable of generating singlet oxygen represent a source of artifactual data in scintillation proximity assays measuring phosphopeptide binding to SH2 domains.

Pai JJ, Kirkup MP, Frank EA, Pachter JA, Bryant RW.

Anal Biochem. 1999 May 15;270(1):33-40. Erratum in: Anal Biochem 1999 Dec 15;276(2):262.


Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution.

Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA, Penning TM.

Mol Endocrinol. 1997 Dec;11(13):1971-84. Erratum in: Mol Endocrinol 1999 Nov;12(11):1763.


The disintegrin eristostatin interferes with integrin alpha 4 beta 1 function and with experimental metastasis of human melanoma cells.

Danen EH, Marcinkiewicz C, Cornelissen IM, van Kraats AA, Pachter JA, Ruiter DJ, Niewiarowski S, van Muijen GN.

Exp Cell Res. 1998 Jan 10;238(1):188-96.


A guide to financial planning.

Pachter JA.

Nurs Spectr (Wash D C). 1997 Jun 2;7(11):10. No abstract available.


Endothelin (ETA) receptor number and calcium signalling are up-regulated by protein kinase C-beta 1 overexpression.

Pachter JA, Mayer-Ezell R, Cleven RM, Fawzi AB.

Biochem J. 1993 Aug 15;294 ( Pt 1):153-8.


Regulation of phospholipid hydrolysis and second messenger formation by protein kinase C.

Bishop WR, Pachter JA, Pai JK.

Adv Enzyme Regul. 1992;32:177-92.


Ca2+ channel agonists enhance thyrotropin-releasing hormone-induced inositol phosphates and prolactin secretion.

Pachter JA, Law GJ, Dannies PS.

Eur J Pharmacol. 1991 Apr 3;195(3):373-9.


Multiple receptors coupled to adenylate cyclase regulate Na-H exchange independent of cAMP.

Ganz MB, Pachter JA, Barber DL.

J Biol Chem. 1990 Jun 5;265(16):8989-92.


Supplemental Content

Loading ...
Support Center